Two of Chi­na's top PD-(L)1 play­ers team up on CT­LA-4 in $200M deal

Now that the PD-(L)1 craze has (large­ly) swept through Chi­na, re­sult­ing in the ap­proval of more than a dozen drugs with more to come, two …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.